EP1194587A4 - Mittel und verfahren zum überwachen von antiretroviralen therapien mit proteaseinhibitorenund entscheidungshilfe bei therapien in der behandlung von hiv/aids - Google Patents

Mittel und verfahren zum überwachen von antiretroviralen therapien mit proteaseinhibitorenund entscheidungshilfe bei therapien in der behandlung von hiv/aids

Info

Publication number
EP1194587A4
EP1194587A4 EP00943056A EP00943056A EP1194587A4 EP 1194587 A4 EP1194587 A4 EP 1194587A4 EP 00943056 A EP00943056 A EP 00943056A EP 00943056 A EP00943056 A EP 00943056A EP 1194587 A4 EP1194587 A4 EP 1194587A4
Authority
EP
European Patent Office
Prior art keywords
hiv
aids
treatment
methods
protease inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00943056A
Other languages
English (en)
French (fr)
Other versions
EP1194587A1 (de
Inventor
Neil T Parkin
Rainer A Ziermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monogram Biosciences Inc
Original Assignee
Virologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/591,899 external-priority patent/US6869759B1/en
Application filed by Virologic Inc filed Critical Virologic Inc
Publication of EP1194587A1 publication Critical patent/EP1194587A1/de
Publication of EP1194587A4 publication Critical patent/EP1194587A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP00943056A 1999-06-22 2000-06-22 Mittel und verfahren zum überwachen von antiretroviralen therapien mit proteaseinhibitorenund entscheidungshilfe bei therapien in der behandlung von hiv/aids Withdrawn EP1194587A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US338323 1989-04-17
US33832399A 1999-06-22 1999-06-22
US591899 2000-06-12
US09/591,899 US6869759B1 (en) 1999-06-22 2000-06-12 Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
PCT/US2000/017178 WO2000078996A1 (en) 1999-06-22 2000-06-22 Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Publications (2)

Publication Number Publication Date
EP1194587A1 EP1194587A1 (de) 2002-04-10
EP1194587A4 true EP1194587A4 (de) 2005-07-06

Family

ID=26991134

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00943056A Withdrawn EP1194587A4 (de) 1999-06-22 2000-06-22 Mittel und verfahren zum überwachen von antiretroviralen therapien mit proteaseinhibitorenund entscheidungshilfe bei therapien in der behandlung von hiv/aids

Country Status (5)

Country Link
EP (1) EP1194587A4 (de)
AU (1) AU5758200A (de)
BR (1) BR0011939A (de)
CA (1) CA2375905A1 (de)
WO (1) WO2000078996A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1185712B8 (de) 1999-05-28 2005-10-19 Virco Bvba Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz
US7138231B2 (en) 2000-09-15 2006-11-21 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US6869759B1 (en) 1999-06-22 2005-03-22 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US7186506B1 (en) 2000-06-12 2007-03-06 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
EP2011889B1 (de) 2000-04-18 2011-09-28 Virco BVBA Verfahren zum Messen des Medikamentenwiderstands gegen HCV
AU2001290923A1 (en) * 2000-09-15 2002-03-26 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
RU2318213C2 (ru) 2000-10-20 2008-02-27 Вирко Бвба Новые мутационные профили обратной транскриптазы вич-1, коррелирующие с фенотипической резистентностью к лекарственным средствам
WO2002099387A2 (en) * 2001-06-04 2002-12-12 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
US7384734B2 (en) 2002-02-15 2008-06-10 Monogram Biosciences, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
EP1520247B1 (de) 2002-07-01 2009-05-27 Tibotec Pharmaceuticals Ltd. Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
ATE375400T1 (de) * 2002-07-01 2007-10-15 Tibotec Pharm Ltd Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren
JP2005536200A (ja) 2002-07-01 2005-12-02 バイロロジック，インコーポレーテッド プロテアーゼ阻害剤に対する病原性ウイルスの感受性を決定するための組成物および方法
EP1522039B1 (de) 2002-07-01 2008-06-04 Tibotec Pharmaceuticals Ltd. Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
JP2006506967A (ja) 2002-07-01 2006-03-02 バイロロジック，インコーポレーテッド プロテアーゼ阻害剤に対する病原性ウイルスの感受性を決定するための組成物および方法
US20100173282A1 (en) 2007-05-25 2010-07-08 Tibotec Pharmaceuticals Ltd. Mutational profile in hiv-1 gag cleavage site correlated with phenotypic drug resistance

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766842A (en) * 1994-09-16 1998-06-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of a protein to a drug targeted thereagainst

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
PETROPOULOS C J ET AL: "The N88S amino acid substitution in HIV-1 protease is associated with increased susceptibility to amprenavir", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 39, 1999, & 39TH INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY; SAN FRANCISCO, CALIFORNIA, USA; SEPTEMBER 26-29, 1999, pages 495, XP001204895 *
See also references of WO0078996A1 *
SMIDT M L ET AL: "A MUTATION IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE AT POSITION 88 LOCATED OUTSIDE THE ACTIVE SITE CONFERS RESISTANCE TO THE HYDROXYETHYLUREA INHIBITOR SC-55389A", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 41, no. 3, March 1997 (1997-03-01), pages 515 - 522, XP000926728, ISSN: 0066-4804 *
ZHANG YI-MING ET AL: "Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites", JOURNAL OF VIROLOGY, vol. 71, no. 9, 1997, pages 6662 - 6670, XP002316390, ISSN: 0022-538X *
ZIERMANN R ET AL: "A MUTATION IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE, N88S, THAT CAUSES IN VITRO HYPERSENSITIVITY TO AMPRENAVIR", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 9, May 2000 (2000-05-01), pages 4414 - 4419, XP002908352, ISSN: 0022-538X *

Also Published As

Publication number Publication date
EP1194587A1 (de) 2002-04-10
WO2000078996A9 (en) 2002-07-11
CA2375905A1 (en) 2000-12-28
AU5758200A (en) 2001-01-09
WO2000078996A1 (en) 2000-12-28
BR0011939A (pt) 2002-03-12

Similar Documents

Publication Publication Date Title
GB0111872D0 (en) Therapeutic agents and methods
AU7186501A (en) Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
EP1194587A4 (de) Mittel und verfahren zum überwachen von antiretroviralen therapien mit proteaseinhibitorenund entscheidungshilfe bei therapien in der behandlung von hiv/aids
IL148034A0 (en) Methods of treating nuclear factor-kappa b mediated diseases and disorders
IL139915A0 (en) Improved methods and apparatus for multi-photon photo-activation of therapeutic agents
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
AU2003278816A8 (en) Ss-l-2'-deoxynucleosides for the treatment of resistant hbv strains and combination therapies
HUP0500560A3 (en) Mixtures of mushroom enzymes and the use thereof for treating maldigestion
PL366216A1 (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
EP1283702A4 (de) Medizinische verbandsanordnung und verfahren deren anwendung
EP1360965A4 (de) Verfahren zur behandlung von krankheiten in zusammenhang mit einer abnahme der expression des aop-1-gens oder aop-1 und mittel zur behandlung der krankheiten
EP1217963A4 (de) Vorrichtungen und verfahren zur behandlung von gewebe
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU1227302A (en) System and method for optimizing drug therapy for the treatment of diseases
EP1392292A4 (de) Pyranoindazole und ihre verwendung in der glaukombehandlung
EP1015642A4 (de) Mittel und methoden zur aufzeichnung einer antiretroviralen therapie mit nucleosid-reverse transkriptase-inhibitoren und leitfaden zu therapeutischen entscheidungen in der hiv/aids-behandlung
EP1191941A4 (de) Methode der prophylaxe und/oder behandlung von erkrankungen
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
EP1322779A4 (de) Mittel und methoden, um eine antiretrovirale proteaseinhibitor therapie zu vervolgen, und therapeutische richtlinien für die behandlung von hiv/aids
EP1213018A4 (de) Prophylaktische und therapeutische mittel für augenerkrankungen
EP1463495A4 (de) Mittel und verfahren zur krebsbehandlung
AU5754701A (en) Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
EP1320402A4 (de) Gerät zur behandlung von hämorrhoiden und zur prostatamassage
EP1359975A4 (de) Okulare iontophoretische vorrichtung und anwendungsmethode
IL153201A0 (en) Methods of treating viral diseases with il-18 and il-18 combinations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020114

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050524

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MONOGRAM BIOSCIENCES, INC.

17Q First examination report despatched

Effective date: 20060824

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091006